Press release from Companies

Published: 2021-03-25 20:35:03

Double Bond Pharmaceutical International AB: DBP International AB: New patent application for SI-053

Double Bond Pharmaceutical International AB (publ) ("DBP" or "The Company", corporate identity number 556991-6082) has today, March 25, 2021, filed another patent application regarding the Company's front-line product SI-053.

DBP's first patent family for SI-053, which protects a formulation, has been granted in Europe, USA, Eurasia and India and is also expected to be granted in other important markets during 2021-2022. With today's patent application, DBP has started work with the next patent family to further broaden the patent protection for the product.

"With very promising preclinical results, we are very optimistic about SI-053's therapeutic market potential - comments Igor Lokot, CEO of DBP. - We will ensure market exclusivity for our product as a prerequisite for their successful global commercialization."

More about Temodex/SI-053: Temodex, which is a locally acting formulation of temozolomide developed by RI PCP in Minsk, Belarus, is registered for marketing as the first-line treatment of glioblastoma within Belarus since 2014. Temodex was acquired by DBP in autumn 2015 and is now being prepared under the name SI-053 to pass through all the tests and trials required for registration within the EU and globally. Video presentation: https://youtu.be/iweOQPq316o



This disclosure contains information that DBP is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 25-03-2021 20:35 CET.

____________________________________________________________________

Full Company Name:   Double Bond Pharmaceutical International AB (publ)

Corporate identity:       556991-6082

Stock short name:       DBP B

Share ISIN code:          SE0007185525

For more info, contact

Igor Lokot, CEO

Homepage: http://www.doublebp.com/

E-mail: info@doublebp.com

Follow us on LinkedIn and Twitter!

_______________________________________________________________________________

Information on Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.

Läs mer hos Cision
Read more about Double Bond Pharmaceutical International AB

Subscription